Claudin18.2(CLDN18.2)ÊÇClaudinÂѰ×ÖʼÒ×åµÄÒ»Ô±£¬Î»ÓÚϸ°ûĤÍâò£¬Ñо¿±íÃ÷Õý³£Çé¿öϽöµÍˮƽ±í´ïÓÚθճĤ·Ö»¯ÉÏÆ¤Ï¸°û£¬µ«ÔÚ²¡Àí״̬Ï£¬Claudin18.2ÔÚ¶àÖÖÖ×ÁöÖÐÓеıí´ïÏÔÖøÉϵ÷£¬°üÂÞ80%µÄ賦µÀÏÙÁö¡¢60%µÄÒÈÏÙÖ×Áö£¬´ËÍ⻹¿É¼ûÓÚʳ¹Ü°©¡¢Âѳ²°©ºÍ·ÎÏÙ°©µÈ£¬ÊǾßÓÐDZÁ¦ÖÎÁư©Ö¢µÄÈÈÃŰеãÖ®Ò»¡£
ͼƬÀ´Ô´£ºTher Adv Med Oncol 2024, Vol. 16: 1–18
Ò» Claudin18.2µÄ±í´ïºÍ¼ì²âÒªÁì
Claudin¼Ò×åÖÁÉÙÓÐ27¸ö³ÉÔ±£¬¾ùÊǶ¨Î»ÓÚϸ°ûĤÍâòµÄ¿çĤÂѰף¬Æä½á¹¹¾ßÓи߶ÈÒ»ÖÂÐÔ£º°üÂÞ4¸ö¿çÄ¤ÇøºÍ2¸ö°ûÍâ»·£¬ÆäÖÐNH2¶ËºÍCOOH¶ËλÓÚ°ûÄÚ£¬¾ßÓÐÁ½¸ö°ûÍâ»·¡£ÕâÖֽṹʹClaudin½ôÃÜÂѰ׼Ò×åÄܹ»ÓÐЧά³ÖÉÏÆ¤Ï¸°ûºÍÄÚÆ¤Ï¸°ûµÄ¼«ÐÔ£¬´Ó¶øÓÐЧµ÷¿ØÏ¸°ûÅÔͨ͸ÐԺ͵絼¡£
ClaudinÂѰ×ÊÇϸ°û¼ä½ôÃÜÁ¬½ÓµÄÖØÒª½á¹¹ÂѰף¬ÆäÑÇÐÍClaudin18.2£¨CLDN18.2£©ÌØÒìÐÔ±í´ïÓÚ·Ö»¯µÄθÉÏÆ¤Ï¸°û£¬²¢ÔÚϸ°û¶ñ±ä¹ý³ÌÖб»¹ý¶È¼¤»î¡£Claudin18.2µÄÒì³£±í´ï»á¸Ä±ä½ôÃÜÁ¬½ÓÂѰ׵ÄÕý³£½á¹¹¼°¹¦Ð§£¬´Ó¶øÊ¹Ï¸°û¼«ÐÔ¶ªÊ§£¬ÔÊÐíÓªÑøÎïÖʼ°ÆäËû¶ÔÖ×Áöϸ°û´æ»îºÍÉú³¤µÄ±ØÐëÒò×ÓÀ©É¢£¬ÔÚÖ×Áöϸ°ûµÄ×ªÒÆºÍÖ×Áöϸ°ûµÄÓªÑø¹©Ó¦ÖÐÆðµ½ÖØÒª×÷Óá£
Ŀǰ¼ì²âCLDN18.2±í´ï½ÏΪ³ÉÊìµÄÒªÁìÊÇÃâÒß×éÖ¯»¯Ñ§È¾É«£¨IHC£©¡£Claudin18.2µÄ¿¹ÌåÖÖÀàĿǰ¹úÄÚ»ñÅúµÄ¼ì²â¿¹Ìå20¼Ò+£¬´ó¶àÊý¹ØÓÚClaudin-18.2ÔÚθ°©Öбí´ïÂʵı¨µÀÊÇ»ùÓÚʹÓÃÓëClaudin-18.1ºÍClaudin-18.2ÔÚC¶ËÅäºÏ±íλµÄ¿¹Ìå½øÐÐÃâÒßȾɫµÄ½á¹û¡£Ò»°ã½ÓÄÉȾɫǿ¶È¼°ÑôÐÔϸ°ûÂÊ×÷ΪCLDN18.2±í´ïµÄ¶¨Á¿·ÖÎöÖ¸±ê£¬È¾É«Ç¿¶È¿É·ÖΪ0£¨Ï¸°ûĤ»òϸ°ûÖÊÎÞ·´Ó³£©¡¢1+£¨Ï¸°ûĤ»òϸ°ûÖÊÈõ·´Ó³ÐÔ£©¡¢2+£¨Ï¸°ûĤ»òϸ°ûÖÊÖз´Ó³£©¡¢3+£¨Ï¸°ûĤ»òϸ°ûÖÊÇ¿·´Ó³ÐÔ£©£¬Ï±í»ã×ܽüÄêÀ´ÎÄÏ×±¨µÀÏà¹ØÑо¿¼°CLDN18.2ÑôÐÔÅжÁÒªÁ죺
ͼƬÀ´Ô´£ºÍøÂç
¶þ Ö¸ÄÏÍÆ¼ö
1 ±í¸ñÍÆ¼öÆ·¼¶ÓÉ2023°æµÄ¢ó¼¶ÍƼö¸ÄΪ2024°æ¢ò¼¶ÍƼö
2 ×¢ÊͲ¿ÃÅ
Claudin 18.2ͨ¹ýÃâÒß×黯Ðмì²â£¬Ä¿Ç°ÑôÐÔÅжÁ³ß¶È½öÀ´×ÔÁÙ´²ÊÔÑé¡£Claudin 18.2ÑôÐÔÓÉÖ×Áöϸ°ûÍêÕû¡¢»ùµ×Íâ²à»òÍâ²àĤȾɫµÄÇ¿¶È£¬ÒÔ¼°Ö×Áöϸ°ûĤ×ÅÉ«ËùÕ¼°Ù·Ö±ÈÁ½¸ö·½Ãæ¾ö¶¨£¬µ«²îÒìµÄÁÙ´²Ñо¿½ÓÄɲîÒìµÄÅжÁ³ß¶È¡£
Èý ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿²¡ÀíÏîÄ¿ÉÏÐÂ
ÎÒÃÇÔËÓÃÃâÒß×黯£¬ÍêÃÀÚ¹ÊÍClaudin 18.2±í´ï£¬½ô¸úÖ¸ÄϸüУ¬¸üÈ«ÃæÖúÁ¦ÁÙ´²¡£
1 ²úÎï¼ò½é
ÅãͬÕï¶ÏClaudin 18.2ÃâÒß×黯£¬¶ÔÓÚClaudin 18.2±í´ïÑôÐÔµÄθ°©»òÆäËûʵÌåÁö»¼Õߣ¬Ô½ÔçÈ·¶¨Claudin 18.2ÂѰױí´ï״̬£¬°ÐÏòÖÎÁƲÅÓпÉÄÜÔ½´ó»ñÒæ¡£
2 ¼ì²âÒªÁì
ÃâÒß×éÖ¯»¯Ñ§È¾É«
ÏÔ΢¾µ¾µ¼ì
3 Ñù±¾ÀàÐÍ
×éÖ¯£¨À¯¿é¡¢·ÀÍÑ°×Æ¬»òÐÂÏÊ×éÖ¯£©
4 ¼ì²âÖÜÆÚ
4¸öÊÂÇéÈÕ¡£
5 ÊÊÓÃÈËȺ
θ°©»¼Õß
ʵÌåÁö»¼Õß
ËÄ ²Î¿¼ÎÄÏ×
[1] Günzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93(2):525-569.
[2] Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668.
[3] Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.
[4] 2024 CSCOθ°©ÕïÁÆÖ¸ÄÏ